John San Marco’s Insights on the Downturn in Consumer Discretionary Stocks: A Personal and Approachable Chat Join us as we delve into the world of investing with John San Marco, the savvy Portfolio Manager at Neuberger Berman. Recently, he graced us with his presence on ‘Closing Bell Overtime’, where he shared his thoughts on the…
The Curious Case of The Bancorp, Inc.: A Tale of Investor Rights Once upon a time, in the bustling city of New York, there was a little-known law firm named Rosen Law Firm. This global powerhouse, known for its unwavering commitment to investor rights, had recently taken notice of an intriguing situation involving The Bancorp,…
Understanding Your Options After Suffering a Loss on Intellia Therapeutics, Inc. (NTLA) Investment Losing money on a stock investment can be a disheartening experience, especially when the company in question is one that held great promise. One such company that has recently seen its stock value decrease significantly is Intellia Therapeutics, Inc. (NTLA). If you…
Suffered a Loss on Your enCore Energy Corp. Investment? Here’s What You Can Do If you’ve been following the stock market closely, you might have noticed some turbulence in the energy sector, specifically with enCore Energy Corp. (NASDAQ: EU). The company’s stock has taken a hit, leaving many investors feeling disheartened and wondering what their…
Atkore Inc. Securities Class Action Lawsuit: What Does It Mean for Investors and the World? On March 31, 2025, in New York, NY, a securities class action lawsuit was filed against Atkore Inc. (NYSE: ATKR) alleging violations of the federal securities laws. The complaint, which can be found on Zilkha Law Firm’s website, asserts that…
Velo3D’s Q4 2024 Earnings Call: A Quirky and Curious Peek Behind the Scenes Once upon a time, in a land of innovation and technology, there was a company called Velo3D, Inc. (OTC:VLDX). And just like Cinderella’s invitation to the royal ball, we, the curious investors and tech enthusiasts, were invited to the grand event of…
Vivos Therapeutics, Inc. (VVOS) Surprises with Narrower-than-Expected Quarterly Loss In a recent financial update, Vivos Therapeutics, Inc. (VVOS) reported a quarterly loss of $0.28 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.43. This represents a significant improvement compared to the loss of $3.05 per share reported in the…
Soho House & Co’s (SHCO) Surprising Quarterly Loss: A Closer Look In a recent financial report, Soho House & Co (SHCO) announced a quarterly loss of $0.10 per share, which was a slight miss compared to the Zacks Consensus Estimate of a loss of $0.07. This disappointing result represents a 50% increase from the loss…
